Cantor Fitzgerald Downgrades Soleno Therapeutics (NASDAQ:SLNO) to Hold

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by equities researchers at Cantor Fitzgerald from an “overweight” rating to a “hold” rating in a report issued on Monday, MarketBeat reports. They presently have a $53.00 price objective on the stock, down from their prior price objective of $123.00. Cantor Fitzgerald’s price target indicates a potential upside of 1.24% from the company’s previous close.

A number of other research firms have also recently weighed in on SLNO. HC Wainwright cut their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Oppenheimer cut their price objective on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Finally, Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a report on Tuesday, January 13th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Soleno Therapeutics currently has an average rating of “Hold” and an average price target of $93.90.

Soleno Therapeutics Trading Up 0.2%

SLNO stock opened at $52.35 on Monday. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a twelve month low of $29.43 and a twelve month high of $90.32. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 227.62 and a beta of -2.81. The firm’s fifty day simple moving average is $38.17 and its two-hundred day simple moving average is $47.80.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its holdings in shares of Soleno Therapeutics by 12.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Soleno Therapeutics in the fourth quarter worth about $38,000. Seven Fleet Capital Management LP bought a new position in shares of Soleno Therapeutics in the fourth quarter worth about $6,023,000. Virtu Financial LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth about $1,059,000. Finally, Empowered Funds LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth about $69,000. 97.42% of the stock is currently owned by institutional investors.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash (about $2.9B), giving SLNO shareholders an immediate cash premium and a clear near‑term exit/liquidity event. Read More.
• Neutral Sentiment: Some research shops have set conservative near‑term views (reaffirmations / “peer perform” ratings) as the deal closes and integration risk becomes the focus; these are neutral for deal economics but can mute momentum. Read More.
• Negative Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT™ XR, citing the acquirer’s plan to sharpen focus on the U.S. market — this reduces near‑term international upside and could lower future revenue projections for the combined company. Read More.
• Negative Sentiment: Dozens of law firms have filed or are soliciting plaintiffs in securities class actions tied to Soleno’s 2025 DCCR/VYKAT XR trial/launch setbacks; litigation risk could create damages exposure, distraction and potential deal complications. Read More.
• Negative Sentiment: Multiple firms are investigating whether the $53/share deal is fair to public shareholders and several analysts have downgraded or cut targets — these actions can pressure the stock and may prompt negotiation or litigation over price. Read More.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.